Trial Outcomes & Findings for To Evaluate the Influence of (LUA Probiotics) on Uric Acid (NCT NCT06969469)
NCT ID: NCT06969469
Last Updated: 2026-06-22
Results Overview
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later. Blood sampling points were week 0, week 2, week 6
Recruitment status
COMPLETED
Target enrollment
20 participants
Primary outcome timeframe
Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood sampling were at week 0, week 2, week 6.
Results posted on
2026-06-22
Participant Flow
Participant milestones
| Measure |
Test Group - Phase 1 + Phase 2
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
The 20 subjects were given the Placebo and test article in the different study period:
Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
There were 20 subjects participating in Phase 1, and the same 20 subjects were also included at the end, and no one withdrew from the clinical trial. Then, the same 20 subjects entered Phase 2, and the same 20 subjects were also included at the end, and no one withdrew from the clinical trial.
|
|---|---|
|
Test group - Phase 1
STARTED
|
20
|
|
Test group - Phase 1
COMPLETED
|
20
|
|
Test group - Phase 1
NOT COMPLETED
|
0
|
|
Test group - Phase 2
STARTED
|
20
|
|
Test group - Phase 2
COMPLETED
|
20
|
|
Test group - Phase 2
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
To Evaluate the Influence of (LUA Probiotics) on Uric Acid
Baseline characteristics by cohort
| Measure |
Test Group - Phase 1 + Phase 2
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
The 20 subjects were given the Placebo and test article in the different study period:
Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=20 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
12 Participants
n=20 Participants
|
|
Age, Categorical
>=65 years
|
8 Participants
n=20 Participants
|
|
Age, Continuous
|
61.4 years
STANDARD_DEVIATION 9.2 • n=20 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=20 Participants
|
|
Sex: Female, Male
Male
|
15 Participants
n=20 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Asian
|
20 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
|
Region of Enrollment
Taiwan
|
20 participants
n=20 Participants
|
PRIMARY outcome
Timeframe: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood sampling were at week 0, week 2, week 6.This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later. Blood sampling points were week 0, week 2, week 6
Outcome measures
| Measure |
Test Group
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
Give the Placebo and test article: Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
uric acid-week 0
|
8.4 mg/dL
Standard Deviation 0.8
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
glucose ac-week 0
|
96.1 mg/dL
Standard Deviation 11.6
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
TG-week 0
|
135.9 mg/dL
Standard Deviation 57.0
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
TC-week 0
|
187.8 mg/dL
Standard Deviation 41.0
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
HDL-week 0
|
48.8 mg/dL
Standard Deviation 9.0
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
LDL-week 0
|
121.2 mg/dL
Standard Deviation 34.2
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
uric acid-week 2
|
8.0 mg/dL
Standard Deviation 0.8
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
glucose ac-week 2
|
96.9 mg/dL
Standard Deviation 10.7
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
TG-week 2
|
139.5 mg/dL
Standard Deviation 59.1
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
TC-week 2
|
189.4 mg/dL
Standard Deviation 36.5
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
HDL-week 2
|
50.7 mg/dL
Standard Deviation 7.9
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
LDL-week 2
|
119.1 mg/dL
Standard Deviation 29.2
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
uric acid-week 6
|
7.9 mg/dL
Standard Deviation 1.1
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
glucose ac-week 6
|
97.4 mg/dL
Standard Deviation 10.7
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
TG-week 6
|
138.1 mg/dL
Standard Deviation 68.5
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
TC-week 6
|
186.1 mg/dL
Standard Deviation 34.2
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
HDL-week 6
|
50.1 mg/dL
Standard Deviation 7.7
|
|
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
LDL-week 6
|
117.1 mg/dL
Standard Deviation 28.7
|
SECONDARY outcome
Timeframe: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Outcome measures
| Measure |
Test Group
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
Give the Placebo and test article: Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Hct (%)-week 0
|
43.5 percentage
Standard Deviation 3.1
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
RDW-CV (%)-week 0
|
12.8 percentage
Standard Deviation 0.6
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Neutrophil (%)-week 0
|
55.5 percentage
Standard Deviation 9.4
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Lymphocyte (%)-week 0
|
34.8 percentage
Standard Deviation 8.6
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Monocyte (%)-week 0
|
5.8 percentage
Standard Deviation 1.3
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Eosinophil (%)-week 0
|
3.1 percentage
Standard Deviation 1.7
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Basophil (%)-week 0
|
0.7 percentage
Standard Deviation 0.4
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Hct (%)-week 2
|
43.7 percentage
Standard Deviation 2.9
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
RDW-CV (%)-week 2
|
12.9 percentage
Standard Deviation 0.6
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Neutrophil (%)-week 2
|
57.2 percentage
Standard Deviation 7.6
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Lymphocyte (%)-week 2
|
33.5 percentage
Standard Deviation 6.5
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Monocyte (%)-week 2
|
5.7 percentage
Standard Deviation 1.3
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Eosinophil (%)-week 2
|
3.0 percentage
Standard Deviation 1.7
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Basophil (%)-week 2
|
0.7 percentage
Standard Deviation 0.3
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Hct (%)-week 6
|
43.4 percentage
Standard Deviation 3.3
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
RDW-CV (%)-week 6
|
12.8 percentage
Standard Deviation 0.5
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Neutrophil (%)-week 6
|
58.1 percentage
Standard Deviation 9.2
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Lymphocyte (%)-week 6
|
32.5 percentage
Standard Deviation 8.5
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Monocyte (%)-week 6
|
5.8 percentage
Standard Deviation 1.3
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Eosinophil (%)-week 6
|
2.9 percentage
Standard Deviation 1.9
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Basophil (%)-week 6
|
0.7 percentage
Standard Deviation 0.2
|
SECONDARY outcome
Timeframe: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days. Blood samlping were at week 0, week 2 and week 6.This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week 0, week 2 and week 6.
Outcome measures
| Measure |
Test Group
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
Give the Placebo and test article: Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-1β - week 0
|
NA pg/mL
Standard Deviation NA
NA: Not Available. Below the level of detection.
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-6 - week 0
|
27.1 pg/mL
Standard Deviation 97.4
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-10 - week 0
|
16.2 pg/mL
Standard Deviation 47.4
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-13 - week 0
|
6.2 pg/mL
Standard Deviation 27.7
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-17 - week 0
|
0.5 pg/mL
Standard Deviation 1.6
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-18 - week 0
|
354.0 pg/mL
Standard Deviation 199.4
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
TNF-α - week 0
|
0.6 pg/mL
Standard Deviation 2.5
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IFN-γ - week 0
|
2.4 pg/mL
Standard Deviation 5.3
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-1β - week 2
|
NA pg/mL
Standard Deviation NA
NA: Not Available. Below the level of detection.
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-6 - week 2
|
18.1 pg/mL
Standard Deviation 52.9
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-10 - week 2
|
13.9 pg/mL
Standard Deviation 23.7
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-13 - week 2
|
6.7 pg/mL
Standard Deviation 30.0
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-17 - week 2
|
0.4 pg/mL
Standard Deviation 1.7
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-18 - week 2
|
442.6 pg/mL
Standard Deviation 315.4
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
TNF-α - week 2
|
0.7 pg/mL
Standard Deviation 2.5
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IFN-γ - week 2
|
3.2 pg/mL
Standard Deviation 5.7
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-1β - week 6
|
NA pg/mL
Standard Deviation NA
NA: Not Available. Below the level of detection.
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-6 - week 6
|
14.3 pg/mL
Standard Deviation 58.5
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-10 - week 6
|
118.1 pg/mL
Standard Deviation 269.9
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-13 - week 6
|
7.1 pg/mL
Standard Deviation 31.7
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-17 - week 6
|
0.4 pg/mL
Standard Deviation 1.5
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IL-18 - week 6
|
115.9 pg/mL
Standard Deviation 203.8
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
TNF-α - week 6
|
0.4 pg/mL
Standard Deviation 2.0
|
|
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
IFN-γ - week 6
|
37.8 pg/mL
Standard Deviation 83.7
|
SECONDARY outcome
Timeframe: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Outcome measures
| Measure |
Test Group
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
Give the Placebo and test article: Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
The 20 Subjects Should be Detected the Value of Hematology: WBC, PLT (Unit: 10^3 Cells/μL).
WBC (10^3 cells/μL)-week 0
|
5.7 10^3 cells/μL
Standard Deviation 1.0
|
|
The 20 Subjects Should be Detected the Value of Hematology: WBC, PLT (Unit: 10^3 Cells/μL).
PLT (10^3 cells/μL)-week 0
|
233.6 10^3 cells/μL
Standard Deviation 61.4
|
|
The 20 Subjects Should be Detected the Value of Hematology: WBC, PLT (Unit: 10^3 Cells/μL).
WBC (10^3 cells/μL)-week 2
|
6.0 10^3 cells/μL
Standard Deviation 1.6
|
|
The 20 Subjects Should be Detected the Value of Hematology: WBC, PLT (Unit: 10^3 Cells/μL).
PLT (10^3 cells/μL)-week 2
|
229.9 10^3 cells/μL
Standard Deviation 64.4
|
|
The 20 Subjects Should be Detected the Value of Hematology: WBC, PLT (Unit: 10^3 Cells/μL).
WBC (10^3 cells/μL)-week 6
|
6.0 10^3 cells/μL
Standard Deviation 1.2
|
|
The 20 Subjects Should be Detected the Value of Hematology: WBC, PLT (Unit: 10^3 Cells/μL).
PLT (10^3 cells/μL)-week 6
|
232.8 10^3 cells/μL
Standard Deviation 56.3
|
SECONDARY outcome
Timeframe: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Outcome measures
| Measure |
Test Group
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
Give the Placebo and test article: Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
The 20 Subjects Should be Detected the Value of Hematology: Hb, MCHC (Unit: g/dL).
Hb (g/dL)-week 0
|
14.3 g/dL
Standard Deviation 1.1
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hb, MCHC (Unit: g/dL).
MCHC (g/dL)-week 0
|
32.9 g/dL
Standard Deviation 0.7
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hb, MCHC (Unit: g/dL).
Hb (g/dL)-week 2
|
14.4 g/dL
Standard Deviation 1.0
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hb, MCHC (Unit: g/dL).
MCHC (g/dL)-week 2
|
33.0 g/dL
Standard Deviation 0.9
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hb, MCHC (Unit: g/dL).
Hb (g/dL)-week 6
|
14.4 g/dL
Standard Deviation 1.2
|
|
The 20 Subjects Should be Detected the Value of Hematology: Hb, MCHC (Unit: g/dL).
MCHC (g/dL)-week 6
|
33.0 g/dL
Standard Deviation 0.9
|
SECONDARY outcome
Timeframe: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Outcome measures
| Measure |
Test Group
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
Give the Placebo and test article: Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
The 20 Subjects Should be Detected the Value of Hematology: MCV (Unit: fL).
MCV (fL)-week 0
|
91.3 fL
Standard Deviation 3.1
|
|
The 20 Subjects Should be Detected the Value of Hematology: MCV (Unit: fL).
MCV (fL)-week 2
|
91.8 fL
Standard Deviation 3.1
|
|
The 20 Subjects Should be Detected the Value of Hematology: MCV (Unit: fL).
MCV (fL)-week 6
|
91.6 fL
Standard Deviation 3.2
|
SECONDARY outcome
Timeframe: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Outcome measures
| Measure |
Test Group
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
Give the Placebo and test article: Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
The 20 Subjects Should be Detected the Value of Hematology: MCH (Unit: pg).
MCH (pg)-week 0
|
30.1 pg
Standard Deviation 1.2
|
|
The 20 Subjects Should be Detected the Value of Hematology: MCH (Unit: pg).
MCH (pg)-week 2
|
30.3 pg
Standard Deviation 1.0
|
|
The 20 Subjects Should be Detected the Value of Hematology: MCH (Unit: pg).
MCH (pg)-week 6
|
30.2 pg
Standard Deviation 1.1
|
SECONDARY outcome
Timeframe: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Outcome measures
| Measure |
Test Group
n=20 Participants
Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs
Give the Placebo and test article: Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
|
|---|---|
|
The 20 Subjects Should be Detected the Value of Hematology:RBC (Unit: 10^6 Cells/μL).
RBC (10^6 cells/μL)-week 0
|
4.8 10^6 cells/μL
Standard Deviation 0.4
|
|
The 20 Subjects Should be Detected the Value of Hematology:RBC (Unit: 10^6 Cells/μL).
RBC (10^6 cells/μL)-week 2
|
4.8 10^6 cells/μL
Standard Deviation 0.4
|
|
The 20 Subjects Should be Detected the Value of Hematology:RBC (Unit: 10^6 Cells/μL).
RBC (10^6 cells/μL)-week 6
|
4.8 10^6 cells/μL
Standard Deviation 0.4
|
Adverse Events
Patients With Hyperuricemia (Uric Acid Level 7.5 mg/dL or Above)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Jyh-Ming Liou
Department of Internal Medicine, National Taiwan University Hospital
Phone: 0972-651883
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place